ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
ChromaDex has announced that its treatment candidate nicotinamide riboside chloride (NRC) for the rare disease ataxia telangiectasia, has been granted US Food and Drug Administration (FDA) orphan drug and rare paediatric disease status.